Jeremy D Keenan1, Keith P Klugman2, Lesley McGee3, Jorge E Vidal2, Sopio Chochua4, Paulina Hawkins4, Vicky Cevallos5, Teshome Gebre6, Zerihun Tadesse6, Paul M Emerson7, James H Jorgensen8, Bruce D Gaynor1, Thomas M Lietman1. 1. Francis I Proctor Foundation Department of Ophthalmology, University of California, San Francisco. 2. Hubert Department of Global Health, Rollins School of Public Health, Emory University. 3. Respiratory Diseases Branch, Centers for Disease Control and Prevention. 4. Hubert Department of Global Health, Rollins School of Public Health, Emory University Respiratory Diseases Branch, Centers for Disease Control and Prevention. 5. Francis I Proctor Foundation. 6. The Carter Center, Addis Ababa, Ethiopia. 7. The Carter Center, Atlanta, Georgia. 8. University of Texas Health Sciences Center, San Antonio.
Abstract
BACKGROUND: A clinical trial of mass azithromycin distributions for trachoma created a convenient experiment to test the hypothesis that antibiotic use selects for clonal expansion of preexisting resistant bacterial strains. METHODS: Twelve communities in Ethiopia received mass azithromycin distributions every 3 months for 1 year. A random sample of 10 children aged 0-9 years from each community was monitored by means of nasopharyngeal swab sampling before mass azithromycin distribution and after 4 mass treatments. Swab specimens were tested for Streptococcus pneumoniae, and isolates underwent multilocus sequence typing. RESULTS: Of 82 pneumococcal isolates identified before treatment, 4 (5%) exhibited azithromycin resistance, representing 3 different sequence types (STs): 177, 6449, and 6494. The proportion of isolates that were classified as one of these 3 STs and were resistant to azithromycin increased after 4 mass azithromycin treatments (14 of 96 isolates [15%]; P = .04). Using a classification index, we found evidence for a relationship between ST and macrolide resistance after mass treatments (P < .0001). The diversity of STs-as calculated by the unbiased Simpson index-decreased significantly after mass azithromycin treatment (P = .045). CONCLUSIONS: Resistant clones present before mass azithromycin treatments increased in frequency after treatment, consistent with the theory that antibiotic selection pressure results in clonal expansion of existing resistant strains.
BACKGROUND: A clinical trial of mass azithromycin distributions for trachoma created a convenient experiment to test the hypothesis that antibiotic use selects for clonal expansion of preexisting resistant bacterial strains. METHODS: Twelve communities in Ethiopia received mass azithromycin distributions every 3 months for 1 year. A random sample of 10 children aged 0-9 years from each community was monitored by means of nasopharyngeal swab sampling before mass azithromycin distribution and after 4 mass treatments. Swab specimens were tested for Streptococcus pneumoniae, and isolates underwent multilocus sequence typing. RESULTS: Of 82 pneumococcal isolates identified before treatment, 4 (5%) exhibited azithromycin resistance, representing 3 different sequence types (STs): 177, 6449, and 6494. The proportion of isolates that were classified as one of these 3 STs and were resistant to azithromycin increased after 4 mass azithromycin treatments (14 of 96 isolates [15%]; P = .04). Using a classification index, we found evidence for a relationship between ST and macrolide resistance after mass treatments (P < .0001). The diversity of STs-as calculated by the unbiased Simpson index-decreased significantly after mass azithromycin treatment (P = .045). CONCLUSIONS: Resistant clones present before mass azithromycin treatments increased in frequency after treatment, consistent with the theory that antibiotic selection pressure results in clonal expansion of existing resistant strains.
Authors: Adam D Kennedy; Michael Otto; Kevin R Braughton; Adeline R Whitney; Liang Chen; Barun Mathema; Jose R Mediavilla; Kelly A Byrne; Larye D Parkins; Fred C Tenover; Barry N Kreiswirth; James M Musser; Frank R DeLeo Journal: Proc Natl Acad Sci U S A Date: 2008-01-23 Impact factor: 11.205
Authors: Thi Anh Hong Le; Laëtitia Fabre; Philippe Roumagnac; Patrick A D Grimont; Maurice R Scavizzi; François-Xavier Weill Journal: J Clin Microbiol Date: 2007-08-29 Impact factor: 5.948
Authors: Matthew R Moore; Robert E Gertz; Robyn L Woodbury; Genevieve A Barkocy-Gallagher; William Schaffner; Catherine Lexau; Kenneth Gershman; Arthur Reingold; Monica Farley; Lee H Harrison; James L Hadler; Nancy M Bennett; Ann R Thomas; Lesley McGee; Tamara Pilishvili; Angela B Brueggemann; Cynthia G Whitney; James H Jorgensen; Bernard Beall Journal: J Infect Dis Date: 2008-04-01 Impact factor: 5.226
Authors: Jenafir I House; Berhan Ayele; Travis C Porco; Zhaoxia Zhou; Kevin C Hong; Teshome Gebre; Kathryn J Ray; Jeremy D Keenan; Nicole E Stoller; John P Whitcher; Bruce D Gaynor; Paul M Emerson; Thomas M Lietman Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Grace M Lee; Ken Kleinman; Stephen Pelton; Marc Lipsitch; Susan S Huang; Matt Lakoma; Maya Dutta-Linn; Melisa Rett; William P Hanage; Jonathan A Finkelstein Journal: Pediatrics Date: 2017-10-04 Impact factor: 7.124
Authors: Fredrick M Mobegi; Amelieke J H Cremers; Marien I de Jonge; Stephen D Bentley; Sacha A F T van Hijum; Aldert Zomer Journal: Sci Rep Date: 2017-02-16 Impact factor: 4.379
Authors: Ki Wook Yun; Eun Hwa Choi; Hoan Jong Lee; Jin Han Kang; Kyung-Hyo Kim; Dong Soo Kim; Yae-Jean Kim; Byung Wook Eun; Sung Hee Oh; Hye-Kyung Cho; Young Jin Hong; Kwang Nam Kim; Nam Hee Kim; Yun-Kyung Kim; Hyunju Lee; Taekjin Lee; Hwang Min Kim; Eun Young Cho; Chun Soo Kim; Su Eun Park; Chi Eun Oh; Dae Sun Jo; Young Youn Choi; Jina Lee Journal: BMC Infect Dis Date: 2018-06-08 Impact factor: 3.090
Authors: Rebecca A Gladstone; Ebrima Bojang; John Hart; Emma M Harding-Esch; David Mabey; Ansumana Sillah; Robin L Bailey; Sarah E Burr; Anna Roca; Stephen D Bentley; Martin J Holland Journal: Clin Microbiol Infect Date: 2020-08-01 Impact factor: 8.067